World's First Oral TRK Inhibitor By Loxo – Bayer Gets FDA Nod Loxo
Oncology Inc's first commercial medicine turns out to be the first
ever Oral TRK Inhibitor to get a green signal from FDA for the
treatment of NTRK (neurotrophic receptor tyrosine kinase) gene fused
solid tumors in both infants & adults for which no treatment exists
till […]
The post World's First Oral TRK Inhibitor By Loxo – Bayer Gets FDA Nod
appeared first on BioTecNika .
https://www.biotecnika.org/2018/11/worlds-first-oral-trk-inhibitor-by-loxo-bayer-gets-fda-nod/
Biotech News
No comments:
Post a Comment